Who is sponsoring NCT01646255?

NCT01646255 is sponsored by UCB Pharma.

What condition does NCT01646255 study?

NCT01646255 studies Idiopathic Parkinson's Disease.

What drugs are being tested in NCT01646255?

Interventions: Rotigotine, Placebo Patch, L-dopa.

What is the status of NCT01646255?

NCT01646255 is currently COMPLETED.

Last reviewed 2018-03-08 · How we verify

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa

NCT01646255 Phase 3 COMPLETED Results posted

The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.

Details

Lead sponsor	UCB Pharma
Phase	Phase 3
Status	COMPLETED
Enrolment	346
Start date	2012-07
Completion	2014-10

Conditions

Idiopathic Parkinson's Disease

Interventions

Rotigotine
Placebo Patch
L-dopa

Primary outcomes

Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period — From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. A negative mean indicates a reduction of the time off during the conduct of the study

Countries

China